Biotechnology company valuations have dropped significantly during the past year, but not yet to a level that has resulted in a lot of smaller firms selling themselves to big pharma. However, biotech companies are beginning to adjust their expectations in early deal negotiations as declining stock prices impact the number of financing options available to fund ongoing drug development programs, according to Jay Stamatis, vice president and head of business development and acquisitions at AbbVie Inc.
Deal-Making Attitudes Begin To Shift As Funding Options Decline
VC Investors Encourage Companies To Seek Partnerships
An AbbVie executive at Biocom’s partnering conference said small firms are beginning to adjust their expectations due to financial market conditions; deal-makers noted biotechs should see value beyond cash in pharma collaborations.
More from Deals
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.